News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
Rivaroxaban is used to treat venous thromboembolism
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Reinforcing commitment to ethical and sustainable growth
Subscribe To Our Newsletter & Stay Updated
